The journey of Takeda’s gout med Uloric—which turned rocky in recent years—has come to an end in the U.S. | Following some safety setbacks and years of generic competition, Takeda is calling it quits ...

Among the myriad drugmakers laying out their plans for the future at this year’s J.P. Morgan Healthcare Conference, Takeda ...

Riyadh, The Kingdom of Saudi Arabia: Takeda, the global biopharmaceutical company, is pleased to announce a new strategic ...

Takeda-backed Ascentage Pharma Group (AAPG) (ASPHF), which is developing treatments for blood cancers, has set terms for a ...

Ascentage Pharma said on Thursday it aims to raise $126.4 million in an initial public offering in the United States, becoming the first sizeable Chinese firm to seek a listing in the U.S. this year.

Amid a rapidly evolving macroenvironment, Takeda is changing up its R&D priorities and investment strategy. | “There's an evolution of our economic model that starts with IRA, and will get worse and ...

Atomi Financial Group Inc. trimmed its holdings in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK – Free Report) ...

More than 250 people — a mix of construction crew members, community and business leaders, and Takeda employees — braved ...

Ascentage Pharma said on Tuesday it was targeting a valuation of $1.75 billion in its initial public offering, becoming the first sizeable Chinese firm to pursue a listing in the U.S. this year.

SUBSCRIBE! Never Miss A Video: <a href=" to read the issue for yourself with all the text? Click right here to buy the issue ...

LEXINGTON, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage ...

Takeda Canada Inc. ("Takeda") announced that, for the third consecutive year, it has received Top Employer® certification for ...